NASDAQ$PODD
Insulet Corp. · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Insulet reported a strong first quarter with revenue increase and raised full year revenue and operating margin guidance.
Insulet Corporation reported a 23% year-over-year increase in revenue for the first quarter of 2024, exceeding guidance. The company raised its full-year revenue and operating margin outlook due to strong performance across all product lines and strategic launches.
- First quarter revenue increased by 23.3% year-over-year to $441.7 million.
- U.S. Omnipod revenue increased by 22.7% and International Omnipod revenue increased by 16.9%.
- Gross margin increased to 69.5%, up 230 basis points year-over-year.
- The company raised its full-year revenue growth expectation to a range of 14% to 18%.
Headline financials
Revenue & EPS history
Insulet · Revenue · Quarterly
$442M
Revenue by segment
Insulet · $433M total across 3 segments · Q3 2023
- U.S. Omnipod$321M+34.6%74.1%
- International Omnipod$101M+15.2%23.4%
- Drug Delivery$10.7M-27.2%2.5%
Forward guidance
Insulet raised its full year revenue and operating margin guidance. For the year ending December 31, 2024, the Company is raising its expected revenue growth to a range of 14% to 18% (previously 12% to 17%) and is raising its expected operating margin to approximately 13.5% (previously approximately 13%).
Tailwinds
- Total Omnipod revenue growth is expected to be 15% to 19%.
- U.S. Omnipod revenue growth is expected to be 17% to 21%.
- International Omnipod revenue growth is expected to be 12% to 15%.
- For the quarter ending June 30, 2024, the Company expects revenue growth of 15% to 18%.
- Total Omnipod revenue is expected to grow 18% to 21% for the quarter ending June 30, 2024.
Headwinds
- Drug Delivery revenue is expected to decline by 60% to 50% for the year ending December 31, 2024.
- Drug Delivery revenue is expected to decline by 75% to 70% for the quarter ending June 30, 2024.
- Currency impact is expected to affect International Omnipod revenue growth.
- Unfavorable results of clinical studies
- Breaches or failures of product or information technology systems, including by cyberattack
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+3.0%
Avg return
Earnings day
+4.0%
Avg return
5 days after
+5.2%
Avg return
30 days after
65%
41 / 63 earnings
Positive
+20.7%
Q1 2025
Best reaction
-16.8%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.1% | +3.8% | +1.4% | |
| Q4 2025 | +3.5% | +1.2% | -7.8% | |
| Q3 2025 | +2.8% | +3.8% | -3.2% | |
| Q1 2025 | +20.7% | +25.1% | +21.3% | |
| Q4 2024 | -1.9% | -6.1% | -6.9% | |
| Q3 2024 | +12.0% | +15.0% | +10.9% | |
| Q2 2024 | -4.3% | +2.2% | +12.8% | |
| Q1 2024 | -5.5% | -1.9% | +9.0% | |
| Q4 2023 | -4.3% | -13.4% | -14.6% | |
| Q3 2023 | +18.1% | +17.5% | +39.6% | |
| Q2 2023 | -11.9% | -13.6% | -31.6% | |
| Q1 2023 | +2.4% | -0.4% | -12.4% | |
| Q4 2022 | +2.3% | -4.0% | +7.8% | |
| Q3 2022 | +19.6% | +16.3% | +17.7% | |
| Q2 2022 | +2.4% | -0.8% | -2.5% | |
| Q1 2022 | -16.8% | -23.0% | -13.9% | |
| Q4 2021 | +8.9% | +12.9% | +7.4% | |
| Q3 2021 | -1.3% | +2.0% | -15.6% | |
| Q2 2021 | -1.3% | +0.1% | +8.4% | |
| Q1 2021 | -11.4% | -13.0% | +2.8% | |
| Q4 2020 | +2.3% | +1.0% | +1.0% | |
| Q3 2020 | +14.6% | +14.4% | +16.0% | |
| Q2 2020 | +1.1% | -7.7% | -4.9% | |
| Q1 2020 | +5.4% | +6.8% | -13.3% | |
| Q4 2019 | -13.2% | -8.4% | -14.2% | |
| Q3 2019 | +9.9% | +16.4% | +26.5% | |
| Q2 2019 | +18.4% | +26.0% | +30.0% | |
| Q1 2019 | +14.0% | +20.9% | +29.4% | |
| Q4 2018 | +5.1% | +7.7% | +6.6% | |
| Q3 2018 | +0.4% | -2.4% | -4.9% | |
| Q2 2018 | +2.4% | +2.6% | +24.3% | |
| Q1 2018 | -3.6% | -4.3% | +9.0% | |
| Q4 2017 | +3.6% | -1.1% | +8.6% | |
| Q3 2017 | +18.9% | +22.7% | +21.0% | |
| Q2 2017 | +6.5% | +8.6% | +15.5% | |
| Q1 2017 | -5.8% | -4.6% | +0.9% | |
| Q4 2016 | -5.2% | +0.7% | -7.2% | |
| Q3 2016 | +9.9% | +10.3% | +3.9% | |
| Q2 2016 | +18.5% | +23.3% | +22.2% | |
| Q1 2016 | -4.0% | — | — | |
| Q4 2015 | +9.0% | — | — | |
| Q3 2015 | +13.2% | — | — | |
| Q2 2015 | +10.0% | — | — | |
| Q1 2015 | -11.0% | — | — | |
| Q4 2014 | -4.5% | — | — | |
| Q3 2014 | +5.1% | — | — | |
| Q2 2014 | -2.2% | — | — | |
| Q1 2014 | -14.0% | — | — | |
| Q3 2013 | -3.4% | — | — | |
| Q2 2013 | +10.2% | — | — | |
| Q1 2013 | +12.0% | — | — | |
| Q4 2012 | +9.3% | — | — | |
| Q3 2012 | +4.2% | — | — | |
| Q2 2012 | +4.8% | — | — | |
| Q1 2012 | +2.1% | — | — | |
| Q4 2011 | -3.5% | — | — | |
| Q3 2011 | +0.5% | — | — | |
| Q2 2011 | +2.9% | — | — | |
| Q1 2011 | +0.6% | — | — | |
| Q4 2010 | -2.0% | — | — | |
| Q3 2010 | +2.5% | — | — | |
| Q2 2010 | +0.3% | — | — | |
| Q1 2010 | +11.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro